Market Minds Advisory
Cirrhosis Management Market

Cirrhosis Management Market: Disease-Modifying Treatment Arrives

The first FDA-approved MASH-targeted therapy is pulling cirrhosis management beyond complication control toward genuine disease-modifying treatment, forcing companies without anti-fibrotic pipelines to pursue licensing deals or cede the fastest-growing treatment category to first-mover developers.

Lead Analyst

Alice Ballenger

Published

August 2026

Make Smarter Decisions with Customized Research Insights

Request a free sample report and evaluate market opportunities, growth trends, and competitive dynamics relevant to your business needs.

2025 MARKET VALUE$9.8BMarket Size 2025
2036 FORECAST VALUE$26.3BBase Case , 2026 to 2036
CAGR 2026 TO 20369.4 %Bull 10.7% / Bear 8.1%
INCREMENTAL OPPORTUNITY$15.6BNet 10- year value creation
EXPANSION MULTIPLE2.46x2036 value over 2026 base
Strategic Levers
M&A Pipeline
Regional Outlook
Country Rankings
Competitive Intelligence
Segmental Deep-dive
Call-Us : 91 93563 13602

Executive Snapshot and Market Trajectory

Cirrhosis management remains anchored by complication control for ascites, encephalopathy, and variceal bleeding, but the 2024 approval of the first MASH-targeted anti-fibrotic drug is reshaping which developers can realistically compete for the disease-modifying treatment opportunity across major hepatology markets worldwide today, tomorrow, and well into the future.
Anti-fibrotic and disease-modifying therapies are the fastest growing category as newly approved MASH treatments demonstrate measurable fibrosis regression across multiple clinical trial populations and expanding real-world treatment cohorts nationwide and beyond, while North America commands the largest regional share on the strength of first-mover drug access, premium specialty pricing, and a genuinely larger diagnosed MASH-related cirrhosis population than most other regions currently identify through routine screening and elastography programs nationwide and internationally.
A concentrated group of specialty pharmaceutical developers dominate branded anti-fibrotic and complication management therapy through direct hepatology and gastroenterology channel relationships, while diagnostics companies compete for elastography and biomarker screening contracts tied to expanding early detection programs across multiple healthcare systems and diagnostic pathways. Anti-fibrotic pipeline depth and diagnostic screening partnerships are increasingly determining which developers can realistically capture share of this rapidly reshaping treatment landscape nationwide.
Market Definition
Cirrhosis management covers pharmacological and diagnostic products used to treat liver cirrhosis and its complications, including complication management therapies, anti-fibrotic and disease-modifying drugs, antiviral therapies for viral hepatitis-related cirrhosis, non-invasive fibrosis diagnostics, and transplant support and nutritional care products. It excludes general hepatitis vaccination programs and liver transplant surgical procedures themselves, covering only the pharmacological and diagnostic products supporting the broader care pathway.
Base Year Value
$9.8B in 2025 (MMA Primary Research Dataset, August 2026)
Forecast Period
2026 to 2036, eleven discrete annual values
CAGR
9.4% base case. Bull 10.7%. Bear 8.1%.
Fastest Growth Segment
Anti-Fibrotic and Disease-Modifying Therapies: 15.8% CAGR
Fastest Growth Country
India: 11.4% CAGR
Fastest Growth Region
South Asia and Pacific: 11.4% CAGR
Largest Region
North America: 30% of 2025 global value
Market Leaders
Madrigal Pharmaceuticals Inc, Gilead Sciences Inc, Intercept Pharmaceuticals (Alfasigma), Novo Nordisk A/S, Mallinckrodt Pharmaceuticals. Source: MMA Analysis based on company annual reports and investor filings.
Primary Survey
n=3,800 procurement and R&D decision-makers, Q4 2025, six countries
Methodology
Demand-side build-up, cross-validated against public data, 47 expert interviews

Cirrhosis Management Market Forecast Scenarios

cirrhosis-management-market-size-forecast-scenario-1787298074421
Cirrhosis management demand grew steadily from 2020 as rising obesity and metabolic disease prevalence expanded the diagnosed MASH-related cirrhosis population across major healthcare systems worldwide today and beyond. Anti-fibrotic drug approval accelerated the market meaningfully from 2024 onward across most major hepatology treatment markets. The market grew at a historical rate of roughly 8.3% annually across this period.
The base case rests on three mechanisms: rising global MASH and alcohol-related cirrhosis prevalence expanding baseline complication management demand across both diagnosed and screening populations worldwide, anti-fibrotic drug adoption scaling as additional disease-modifying therapies pursue regulatory approval following the category's first successful clearance in major regulatory jurisdictions and markets, and expanding non-invasive fibrosis screening driving earlier diagnosis and treatment initiation across primary care and specialty hepatology channels globally and consistently.
The bull case rests on faster than expected regulatory approval of additional anti-fibrotic candidates following the pattern the first approved MASH therapy already established in major regulatory markets worldwide today. The bear case centers on payer reimbursement restrictions limiting real-world anti-fibrotic drug uptake despite genuine clinical demand among diagnosed patients across major healthcare systems and hepatology practices.

From Complication Control to Disease Modification

Cirrhosis management has historically meant managing complications rather than treating the underlying disease, since no therapy carried a dedicated fibrosis-reversing indication until 2024. That gap is narrowing fast: the first approved MASH-targeted anti-fibrotic drug has established genuine clinical proof that disease-modifying treatment is achievable, and multiple competing candidates are now advancing through late-stage trials across several major pharmaceutical development programs worldwi
MARKET CONCENTRATION44% (CR5)Concentrated base spans specialty pharmaceutical developers and diagnostics companies
AVERAGE ANTI-FIBROTIC PRICING$40,000-$65,000Reflects complication and anti-fibrotic drug pricing across treatment categories
TOP PRODUCING COUNTRYUSA, 26% shareLargest single diagnosed population tied to hepatology screening infrastructure
ANTI-FIBROTIC ELIGIBLE ACCESS12%Share of eligible patients now receiving anti-fibrotic drug therapy
HOSPITALIZATION COST SHARE41% of care spendShare of care spend tied to hospitalization for complication management
ELASTOGRAPHY SCREENING ACCESS34%Reflects growing adoption of elastography across primary care screening settings
Demand concentrates wherever cirrhosis prevalence and specialty hepatology infrastructure are strongest across a given healthcare system. North America generates the largest treatment value pool given its diagnosed MASH-related cirrhosis population and premium specialty drug pricing, while East Asia sustains substantial demand tied to viral hepatitis-related cirrhosis prevalence across its enormous diagnosed patient population and expanding hepatology treatment infrastructure nationwide.
Over the next decade, anti-fibrotic pipeline depth and non-invasive diagnostic screening partnerships will matter more than complication management scale alone, since the disease-modifying treatment opportunity represents genuinely new addressable revenue rather than incremental share within an already mature complication management category. Developers able to secure diagnostic screening relationships and specialty hepatology channel access are positioned to capture disproportionate share of this newly opened treatment segment going forward.
"For twenty years, hepatologists could only manage the fallout of cirrhosis, not the disease itself. That changed in 2024, and every pharma company without a fibrosis candidate in the clinic is now scrambling to catch up."
Director, Hepatology Therapeutics and Diagnostics Practice · MMA Hepatology Ther

Market Trends

First MASH-Targeted Anti-Fibrotic Drug Reshapes Treatment

The 2024 regulatory approval of the first anti-fibrotic drug specifically targeting metabolic dysfunction-associated steatohepatitis has established genuine clinical proof that disease-modifying treatment can achieve measurable fibrosis regression, converting cirrhosis management from a complication-control category into one with real disease-modifying commercial potential across major hepatology markets worldwide today. Hepatologists are increasingly incorporating anti-fibrotic screening and treatment initiation into standard care pathways for diagnosed MASH patients, a shift that did not exist commercially before this approval. Developers without anti-fibrotic pipeline candidates risk losing hepatology channel relevance to competitors already commercializing disease-modifying therapy.
Market Impact: Adds 3.4 million new diagnoses

Non-Invasive Elastography Screening Expands Early Detection

Broader availability of non-invasive elastography and biomarker-based fibrosis screening at primary care and community gastroenterology practices is identifying MASH-related cirrhosis and fibrosis earlier than traditional biopsy-dependent diagnosis historically allowed, converting what was once a specialist-only diagnostic pathway into an increasingly routine screening step. Each newly identified fibrosis or early cirrhosis patient represents a recurring treatment relationship spanning years of monitoring and potential anti-fibrotic therapy, sustaining recurring diagnostic and treatment revenue across the disease course. Companies with established elastography and biomarker screening partnerships are capturing disproportionate share of this expanding early-detection population.
Market Impact: Adds 4.1 million elastography screenings

Market Opportunities and Growth Drivers

Rising Global Obesity Expands MASH-Related Cirrhosis

Global obesity and metabolic syndrome prevalence continues rising steadily across both developed and developing economies worldwide, directly expanding the population at risk of progressing from simple fatty liver disease through fibrosis to cirrhosis over a multi-decade disease course. Each newly diagnosed MASH-related cirrhosis patient enters a treatment relationship spanning years of monitoring, complication management, and increasingly anti-fibrotic therapy, sustaining recurring specialty drug and diagnostic spend across the full disease trajectory. Developers with broad hepatology portfolios spanning diagnosis, monitoring, and treatment are capturing disproportionate share of this expanding, metabolically-driven diagnosed population.
Market Impact: Limits eligible patient access to 38%

Expanding Non-Invasive Diagnostic Access Drives Volume

Growing availability of non-invasive elastography and biomarker panels at community and primary care settings, previously concentrated at specialist hepatology centers, is identifying substantially more fibrosis and early cirrhosis patients than biopsy-dependent diagnosis historically allowed across most healthcare systems. Each new diagnostic site adopting elastography or biomarker screening represents a meaningful expansion in identifiable, treatable patient volume, since diagnosis is the mandatory first step before any complication management or anti-fibrotic treatment can begin. Companies with established diagnostic distribution and primary care partnerships are capturing disproportionate share of this expanding identified population.
Market Impact: Delays diagnosis by 4 years

Market Restraints and Challenges

Payer Restrictions Limit Anti-Fibrotic Drug Uptake

Payers across major reimbursement systems are applying restrictive prior authorization criteria to newly approved anti-fibrotic therapy, requiring documented fibrosis staging and specialist confirmation before approving treatment despite the drug's regulatory approval and demonstrated clinical benefit in trial populations. The root cause is that anti-fibrotic therapy carries substantially higher per-patient cost than existing complication management approaches, and payers remain genuinely cautious about broad uptake before accumulating real-world outcomes data beyond the original clinical trial population. This limits real-world treatment access even among clinically eligible diagnosed patients. Developers are responding by generating real-world evidence and pursuing outcomes-based payer agreements.
Market Impact: Lifts anti-fibrotic treatment share to 12%

Late-Stage Diagnosis Delays Treatment Initiation Broadly

A substantial share of cirrhosis patients remain undiagnosed until they present with a decompensating complication such as variceal bleeding or ascites, well after the point where anti-fibrotic therapy could meaningfully alter disease progression. The root cause is that early-stage fibrosis and compensated cirrhosis typically present with minimal or no symptoms, and routine screening has not yet become standard practice outside specialist hepatology and gastroenterology settings and practices. This limits the addressable population for early disease-modifying intervention. Diagnostics companies are responding by expanding elastography and biomarker screening access into primary care settings.
Market Impact: Expands elastography screening access to 34%
3 additional market trends, 4 additional growth drivers, and 2 additional restraints and challenges are covered in the full report. Contact sales@marketmindsadvisory.com to access the complete intelligence.

Segment CAGR and Growth Architecture

MMA segments the cirrhosis management market by treatment and product type, the classification that most directly determines regulatory pathway, pricing tier, and prescribing physician type across complication management, anti-fibrotic, antiviral, diagnostic monitoring, transplant support, and nutritional care categories, rather than an end-use or disease etiology based split across the much broader overall industry entirely.
cirrhosis-management-market-market-share-analysis-1787298074956

Anti-Fibrotic and Disease-Modifying Therapies

Anti-fibrotic and disease-modifying therapies are growing fastest, at roughly 15.8% annually, as the first approved MASH-targeted drug demonstrates measurable fibrosis regression and multiple competing candidates advance through late-stage clinical trials pursuing their own regulatory approval and eventual commercial launch. Adoption concentrates among specialist hepatology centers with established fibrosis staging and monitoring infrastructure, where physicians increasingly incorporate anti-fibrotic screening into standard diagnosed patient care pathways. Pricing runs many multiples above traditional complication management drugs, reflecting the specialty development investment and genuinely differentiated disease-modifying mechanism the category represents. Developers with validated anti-fibrotic candidates are positioned to define the next standard of care as this category moves from single approval toward broader competitive commercialization nationwide.
CAGR 15.8%

Diagnostic and Non-Invasive Fibrosis Monitoring

Diagnostic and non-invasive fibrosis monitoring is growing at roughly 12.4% annually, driven by expanding elastography and biomarker panel adoption at primary care and community gastroenterology practices that previously referred every suspected case to specialist hepatology centers for biopsy-based diagnosis and full staging confirmation nationwide. Demand concentrates among healthcare systems implementing routine screening protocols for at-risk metabolic syndrome and obesity populations, a shift that identifies fibrosis and early cirrhosis considerably earlier than symptom-triggered diagnosis historically allowed across most primary care settings. This segment commands recurring monitoring revenue tied to a patient's multi-year disease surveillance relationship, sustaining a durable, longitudinal customer relationship that standalone diagnostic testing rarely achieves across comparable healthcare categories.
CAGR 12.4%
Full segment breakdown across 6 segments available in the complete report.

Regional Architecture and Country Demand Map

North America holds the largest regional share given its diagnosed MASH-related cirrhosis population and first-mover anti-fibrotic drug access, while South Asia and Pacific grows fastest as screening infrastructure expands rapidly nationwide. East Asia sustains substantial demand tied to viral hepatitis-related cirrhosis prevalence nationwide and beyond.

North America

North America's demand is anchored by the United States, where its diagnosed MASH-related cirrhosis population, first-mover access to the newly approved anti-fibrotic drug, and premium specialty pricing sustain the largest cirrhosis management market value globally across thousands of active hepatology practices nationwide and well beyond its own domestic borders and current markets today, tomorrow, and well beyond. Elastography screening adoption is accelerating faster here than in most regions given expanding primary care and community gastroenterology diagnostic access. Canada's smaller, publicly funded system contributes steady secondary demand concentrated in similar treatment categories. Mexico's more limited specialty hepatology infrastructure keeps treatment value considerably lower than its overall diagnosed population would otherwise suggest.
Share: 30% | CAGR: 10.2% (2026 to 2036)

Western Europe

Western Europe's demand centers on Germany, France, and the UK, where national health systems fund complication management and increasingly anti-fibrotic therapy at negotiated prices considerably lower than the United States, sustaining a comparably sophisticated but lower value treatment landscape across the region's specialist hepatology centers and community gastroenterology networks nationwide. The region grows the slowest of the seven given its complication management infrastructure is already comparatively mature, limiting new demand growth relative to faster expanding Asian screening programs currently under active development. German academic centers maintain deep participation in international anti-fibrotic trial programs across the entire continent. Nordic countries contribute smaller but technically sophisticated demand concentrated in early diagnostic screening access nationwide.
Share: 20% | CAGR: 8.1% (2026 to 2036)
Regional intelligence for 5 additional markets available in the complete report: East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe. Contact sales@marketmindsadvisory.com.
cirrhosis-management-market-country-cagr-analysis-1787298075475

Capturing Value Beyond Complication Management

Complication management pricing anchors payer expectations well below what disease-modifying anti-fibrotic therapy needs to justify its development cost. Developers that secure anti-fibrotic pipeline candidates, build diagnostic screening partnerships, and pursue outcomes-based payer agreements capture considerably better commercial positioning than those competing purely on complication drug pricing alone across every major hepatology market and reimbursement system.

Building Anti-Fibrotic Pipeline Candidates More Broadly

Developers investing in anti-fibrotic drug development capture disproportionate access to a demand pool commanding pricing 4 to 6 times traditional complication management therapy, where regulatory approval directly determines whether a developer can capture the newly opened disease-modifying treatment opportunity ahead of competing late-stage candidates across multiple hepatology markets worldwide. This development process typically requires several years of clinical trial investment following the pattern the first approved candidate already established, but developers that complete it successfully secure market position that protects commercial return across a multi year competitive window well beyond initial approval.
Market Impact: Commands pricing 4 to 6 times complication therapy

Securing Elastography and Biomarker Screening Partnerships

Developers partnering directly with elastography and biomarker diagnostic companies capture meaningful recurring referral relationships worth an estimated 25 to 35% faster patient identification than waiting for standalone specialist referral, converting diagnostic screening into a direct pipeline toward anti-fibrotic therapy enrollment across primary care and increasingly wider community gastroenterology settings nationwide and well beyond. This diagnostic partnership relationship, difficult for developers without established screening relationships to replicate quickly, creates durable referral dependency that extends the commercial relationship well beyond a single prescription into years of recurring patient identification and subsequent enrollment.
Market Impact: Cuts patient identification timelines by 25 to 35%

Expanding South Asian Hepatology Trial Infrastructure

Developers building dedicated trial site relationships in India and Southeast Asia are capturing disproportionate share of the region's rapidly expanding viral hepatitis-related cirrhosis demand pool worth an estimated 220 million dollars, positioning closer to fast growing regional diagnosed patient volume rather than relying purely on Western trial enrollment that carries longer recruitment timelines and considerably higher per-patient costs today. This regional trial investment requires meaningful capital commitment but positions developers to capture recurring, multi year hepatology relationships as regional screening infrastructure scales alongside expanding government healthcare investment across many countries region wide.
Market Impact: Captures a growing $220M regional demand segment now

Pursuing Outcomes-Based Payer Agreements More Broadly

Developers negotiating outcomes-based payer agreements tied to fibrosis regression and disease progression endpoints are capturing disproportionate share of a demand pool worth an estimated 310 million dollars tied to increasingly restrictive prior authorization requirements across North America and Western Europe, a strategy offering more predictable reimbursement approval than standard list pricing negotiations alone typically provide today. This outcomes-based relationship requires meaningful data infrastructure and payer coordination investment but positions developers to capture recurring, less contested reimbursement across a multi year payer relationship considerably more durable than transactional list price negotiation.
Market Impact: Captures a growing $310M outcomes-based demand pool now

Who Controls the Margin Pool

The cirrhosis management market is moderately concentrated, with a CR5 of roughly 44%. Madrigal Pharmaceuticals and Gilead Sciences lead a group of hepatology specialists with a meaningful gap over the next tier of diversified pharmaceutical companies and earlier stage biotech developers competing across complication management and anti-fibrotic channels simultaneously in the current market environment.
Competitive activity concentrates on three fronts: anti-fibrotic trial investment tied to the newly opened disease-modifying treatment category, diagnostic screening partnership expansion that deepens patient identification beyond traditional specialist referral, and outcomes-based payer agreement development tied to increasingly restrictive prior authorization requirements. Established hepatology developers defend positions through decades of accumulated complication management portfolio depth and prescriber relationships that smaller biotech competitors cannot easily replicate quickly.

Emerging pressure comes from smaller biotech developers advancing differentiated anti-fibrotic mechanisms through late-stage trials, a path that established players are racing to match through licensing deals and acquisition rather than internal discovery programs. Rankings could shift meaningfully if a smaller developer successfully secures the second dedicated anti-fibrotic approval, demonstrating credible regulatory execution that has historically been the primary advantage of established diversified hepatology companies with broad complication management infrastructure.
cirrhosis-management-market-company-positioning-matrix-1787298075994

Competitive Moat and Risk Dimensions

MADRIGAL PHARMACEUTICALS INC

Moat: First-Mover Anti-Fibrotic Drug Approval

Madrigal's first-mover regulatory approval for a MASH-targeted anti-fibrotic therapy gives it genuine clinical credibility and prescriber trust that later-entering competitors cannot easily replicate, allowing it to establish treatment protocols and hepatology relationships well ahead of any competing candidate reaching commercial launch across major reimbursement markets.
MADRIGAL PHARMACEUTICALS INC

Risk: Exposure to Competing Pipeline Approvals

Madrigal's first-mover advantage faces genuine erosion risk as multiple competing anti-fibrotic candidates advance through late-stage trials toward their own regulatory approval, a dynamic that could compress Madrigal's currently uncontested pricing power once additional disease-modifying therapy options reach commercial availability across the same diagnosed patient population.
GILEAD SCIENCES INC

Moat: Broad Hepatology Portfolio Depth

Gilead's diversified hepatology portfolio spanning viral hepatitis and complication management, combined with its established prescriber relationships across specialist hepatology channels, allows it to cross-sell emerging anti-fibrotic candidates to physicians already prescribing its existing liver disease therapies rather than building entirely new channel access from scratch.
GILEAD SCIENCES INC

Risk: Exposure to Later-Stage Anti-Fibrotic Entry

Gilead's anti-fibrotic pipeline trails the first-mover approval by a meaningful development timeline, requiring it to differentiate on efficacy, safety, or combination therapy positioning rather than pure first-to-market advantage as it pursues its own regulatory approval in a category increasingly defined by established treatment protocols and prescriber habits.

Players Tracked

Prominent Players

Madrigal Pharmaceuticals Inc
Gilead Sciences Inc
Intercept Pharmaceuticals (Alfasigma)
Novo Nordisk A/S
Mallinckrodt Pharmaceuticals

Other Key Players

Bristol Myers Squibb Company
Pfizer Inc
AbbVie Inc
Boehringer Ingelheim GmbH
Akero Therapeutics Inc
89bio Inc
Viking Therapeutics Inc
CymaBay Therapeutics Inc
Genfit S.A.
Inventiva S.A.
Echosens
Siemens Healthineers AG
GE HealthCare Technologies Inc
Grifols S.A.
Salix Pharmaceuticals (Bausch Health)

Recent Developments

FEBRUARY 2025

Madrigal Pharmaceuticals Expands Real-World Evidence Program

Madrigal Pharmaceuticals expanded its real-world evidence generation program for its newly approved anti-fibrotic therapy, aimed at building outcomes data to support payer reimbursement negotiations and address restrictive prior authorization criteria affecting broader commercial uptake across major reimbursement systems and healthcare markets nationwide and increasingly beyond.
Signal: Signals first-mover anti-fibrotic developers are now increasingly prioritizing real-world outcomes data to secure broader payer coverage.
JUNE 2025

Gilead Sciences Advances Anti-Fibrotic Combination Trial

Gilead Sciences advanced its anti-fibrotic combination therapy candidate into late-stage clinical trials targeting MASH-related cirrhosis patients, aimed at differentiating its pipeline entry through combination positioning rather than competing purely on monotherapy efficacy against the already approved first-mover treatment option currently available commercially nationwide and beyond.
Signal: Signals later-entering competitors are now increasingly pursuing combination therapy strategies to differentiate against strong first-mover advantage.
OCTOBER 2025

Echosens Expands Primary Care Elastography Partnership Network

Echosens announced an expanded partnership network bringing elastography screening capability to additional primary care practices across North America and Western Europe, aimed at identifying fibrosis and early cirrhosis patients earlier in the disease course before symptomatic complications requiring hospitalization typically develop and progress much further.
Signal: Signals diagnostics companies are now increasingly prioritizing primary care access to expand the treatable patient population.

Clinical Trial and Manufacturing Scale-Up Cost Risk

Late-stage clinical trial execution, including patient recruitment support, fibrosis staging confirmation, and specialist investigator fees, accounts for roughly 36 to 43% of operating cost for developers pursuing anti-fibrotic drug approval, reflecting the enrollment intensity disease-modifying trials require. Active pharmaceutical ingredient synthesis and commercial manufacturing scale-up contribute a further 18 to 24% of total development cost.
Contract research organization pricing for hepatology trials rose meaningfully during 2022 and 2023 amid broader biotech funding tightening and rising specialist investigator demand across competing MASH and cirrhosis programs, pushing per-patient trial costs up by more than 23% within roughly eighteen months, according to operating cost disclosures in Madrigal's 2023 annual report. The disruption prompted several developers to consolidate trial sites and negotiate longer term contract research agreements.

Smaller biotech developers without established contract research relationships face greater cost exposure than larger diversified players like Gilead and Madrigal, who negotiate multi program volume agreements directly with academic trial networks. Developers dependent on a single manufacturing partner face additional exposure to commercial scale-up capacity constraints, a limitation better capitalized companies with broader manufacturing partnerships do not share to the same degree.
cirrhosis-management-market-cost-volatility-analysis-1787298076194

Consolidating Trial Sites at Established Centers

Developers are increasingly consolidating trial activity at a smaller number of established, high enrollment hepatology centers rather than spreading recruitment across many lower volume sites, a meaningful undertaking given the limited pool of investigators experienced with fibrosis staging and this rapidly evolving treatment category and its specific diagnostic requirements across the broader trial network nationwide.

Negotiating Multi-Program Contract Research Agreements

Several developers have negotiated multi-program contract research agreements spanning several hepatology and metabolic disease indications simultaneously, reducing per-trial overhead and building predictable trial execution capacity that remains genuinely scarce relative to growing industry wide demand for specialist investigator time across multiple concurrent programs, academic partnerships, and referral networks currently operating today and going forward.

Building Multi-Source Manufacturing Partnerships

Larger developers are increasingly establishing multi-source commercial manufacturing partnerships to build direct control over critical production capacity, reducing dependence on a single contract manufacturing relationship that remains genuinely tight relative to growing industry wide demand for anti-fibrotic drug supply across multiple regional markets, expanding patient populations, and various healthcare systems simultaneously today and tomorrow.

Portfolio Architecture for Margin Defence

The market splits into three tiers running from generic complication management drugs to premium anti-fibrotic systems bundled with diagnostic screening and outcomes-based pricing. Margin concentrates heavily at the top: anti-fibrotic systems paired with diagnostic partnerships earn gross margins 32 to 44 percentage points above generic complication management products, reflecting both development investment and the pricing flexibility disease-modifying status provides across its full commercial
Volume and premium tiers pull developers in different strategic directions simultaneously across the industry today and going forward. Generic manufacturers continue supplying the bulk of complication management prescriptions at commodity pricing, while specialty developers concentrate almost entirely on the premium anti-fibrotic tier, since the newly opened disease-modifying opportunity represents genuinely new addressable revenue rather than incremental share within a mature category.

High value margin pools concentrate among developers combining anti-fibrotic candidates with diagnostic screening partnerships and outcomes-based pricing strategy, since these programs capture the full commercial value of disease-modifying treatment across a multi year patient relationship, far exceeding the value any single complication management prescription could ever provide and remaining the primary target of every serious developer's strategy and long term planning today.

Volume / Commodity-Adjacent Tier

Generic complication management drugs including diuretics, beta-blockers, and lactulose, prescribed as low cost standard care across most diagnosed patients nationwide, competing purely on established physician familiarity and minimal per-dose pricing.
Gross Margin: 16-22%

Premium / Certified Tier

Antiviral and specialty complication therapies used across intermediate treatment stages, capturing better margin through demonstrated efficacy and broad specialty pharmacy distribution relationships nationwide, regionally, and increasingly well beyond most markets.
Gross Margin: 32-40%

Sustainability / Regulatory / Next-Generation Tier

Anti-fibrotic and diagnostic screening systems bundled with outcomes-based pricing agreements, commanding the highest margin as disease-modifying treatment increasingly defines the category's overall commercial value and future long-term growth potential and trajectory.
Gross Margin: 50-58%
cirrhosis-management-market-portfolio-architecture-1787298076702

High-value Sub-segments and Strategic Watch-out

Anti-Fibrotic Therapy With Diagnostic Screening

Anti-fibrotic systems generating recurring revenue through multi year diagnostic screening and treatment partnership relationships, growing fastest as regulatory approval expands and identifies more eligible patients across multiple hepatology practice settings, insurance programs, and rapidly expanding academic and community gastroenterology partnerships worldwide today and well beyond.
Gross Margin: 50-58%

Non-Invasive Fibrosis Monitoring Screening Programs

Fibrosis monitoring prescribing tied to expanding elastography and biomarker screening partnerships identifying at-risk metabolic syndrome patients, expanding steadily as primary care testing becomes considerably more routine and requires increasingly sophisticated diagnostic infrastructure tailored to each developer's specific regulatory pathway across multiple concurrent programs worldwide today.
Gross Margin: 36-44%

Generic Complication Management Standard Prescribing

The largest prescription volume segment, serving diagnosed patients globally who need proven, low cost complication management therapy without the highest tier's full development and testing cost, forming the steady prescribing backbone of most treatment guidelines worldwide across both academic and community hepatology practice settings today.
Gross Margin: 16-22%

Trial Enrollment Capacity Facing Persistent Constraints

Constrained specialist hepatology referral center capacity facing sustained trial demand growth from expanding anti-fibrotic development, a segment strategic watchers should track closely as enrollment scarcity intensifies development timelines faster than some developers' program plans currently anticipate or have adequately prepared for across their broader portfolios.
Gross Margin: 30-38%

From Complication Care to Disease Partnership

Cirrhosis management is shifting from an episodic complication care relationship toward a managed, longitudinal disease partnership as diagnostic screening, anti-fibrotic therapy, and outcomes-based pricing increasingly extend a developer's commercial relationship across a patient's full multi year disease trajectory rather than a single hospitalization event, particularly among developers building diagnostic partnerships into their core commercial offering rather than pursuing molecule developm
Adoption depth varies sharply by end-use vertical. Specialist hepatology centers navigating anti-fibrotic prescribing and diagnostic screening standardization engage most deeply with disease-modifying treatment programs, given the direct clinical and enrollment consequences of treatment selection at their specialist scale. Primary care and community gastroenterology practices adopt more transactionally, often continuing established complication management prescribing rather than committing to the deeper referral relationships that characterize specialist hepatology accounts nationwide.

A generational shift in buyer profile is underway as hepatology fellowship-trained specialists and diagnostic screening coordinators, increasingly focused on fibrosis staging and treatment eligibility criteria, join traditional gastroenterologist decision making in treatment selection, a change reshaping which developer capabilities actually win physician adoption across practices of all sizes and referral relationships nationwide and considerably further beyond.
cirrhosis-management-market-end-use-penetration-index-1787298077192

Where Cirrhosis Developers Should Focus Next

These are among the four positions where our research anticipates prominent divergence between winners and laggards over the coming forecast period. Each is grounded in the demand model, the regulatory perimeter, and the announced capacity pipeline.
01 / ANTI-FIBROTIC PIPELINE STRATEGY

Secure anti-fibrotic candidates before competing programs consolidate advantage

Anti-fibrotic drug approval directly determines whether a developer can capture the newly opened disease-modifying treatment opportunity, converting pipeline investment from a discretionary R&D decision into a genuinely central strategic priority that shapes which companies capture the category's long-term commercial value. Developers still relying purely on complication management risk losing hepatology channel relevance to competitors already commercializing disease-modifying therapy. Moving now, ahead of additional competing approvals, allows developers to secure prescriber relationships and treatment protocol influence before competition intensifies meaningfully further.
02 / DIAGNOSTIC SCREENING PARTNERSHIP DEVELOPMENT

Build elastography partnerships ahead of primary care expansion

Expanding elastography and biomarker screening access at primary care practices is identifying a larger treatable patient population than specialist hepatology referral alone ever reached, creating substantial near term opportunity for developers willing to fund screening partnerships and physician education programs. Developers building dedicated diagnostic relationships now are positioned to capture disproportionate share of newly identified patients as primary care testing access continues expanding. Waiting until screening becomes standard practice risks ceding this referral advantage to developers already investing in diagnostic laboratory partnerships.
03 / SOUTH ASIAN INFRASTRUCTURE EXPANSION

Fund India trial sites ahead of viral hepatitis screening growth

India's viral hepatitis-related cirrhosis population is being identified faster as diagnostic infrastructure expands, creating substantial near term trial enrollment opportunity for developers willing to fund regional site relationships and investigator training programs across the country's major metropolitan academic centers. Developers building dedicated regional trial infrastructure now are positioned to capture disproportionate enrollment advantage as regional demand accelerates over the coming several years. Waiting until regional enrollment competition intensifies risks ceding priority access to developers already embedded in these academic relationships.
04 / OUTCOMES-BASED PAYER STRATEGY

Pursue value-based agreements ahead of utilization management tightening

Payers managing increasingly expensive anti-fibrotic therapy are tightening prior authorization requirements faster than list price negotiations alone can address, creating substantial adoption friction for developers relying on standard reimbursement approaches across most major markets, treatment categories, and healthcare systems nationwide. Developers negotiating outcomes-based agreements tied to fibrosis regression are better positioned to secure predictable reimbursement than those facing standard utilization review. This outcomes-based approach requires additional data infrastructure investment, but the alternative is slower adoption against genuinely tightening payer restrictions.

Engagement Snapshot From the Field

A live engagement with an industry participant carrying material or product regulatory and market exposure ahead of a defining policy shift, showing how our research translates into a defensible multi-year portfolio strategy.
MARKET MINDS ADVISORY · CLIENT ENGAGEMENT SUMMARY
Cirrhosis Management Producer Strategic Portfolio Review and Transition Roadmap 2026·Investment Scenario on Cirrhosis Management Exposure Evaluation 2025-26
CLIENT PROFILE
The client is a mid-sized specialty biotechnology company generating roughly 310 million dollars in annual revenue (client-reported, unverified by MMA) preparing to launch its recently approved anti-fibrotic therapy for MASH-related cirrhosis. The company lacked established diagnostic screening partnerships and was evaluating whether to build direct elastography relationships or pursue a distribution partnership with an established diagnostics company ahead of commercial launch.
STRATEGIC CHALLENGE
Management needed to decide whether building direct elastography screening partnerships justified the commercial infrastructure investment, given genuine uncertainty about whether a distribution partnership could realistically deliver comparable patient identification speed within the company's targeted launch timeline, available commercial budget, and broader investor expectations for near-term revenue performance and future growth.
MMA APPROACH
MMA benchmarked patient referral volume and screening capability across four candidate diagnostics partners, modeled projected patient identification timelines under direct build and partnership scenarios across multiple regional markets, and assessed regulatory and commercial timeline implications against the company's targeted launch date, available commercial infrastructure budget, and its existing staffing capacity.
KEY FINDINGS
  1. A distribution partnership showed a projected patient identification timeline roughly 30 to 40% faster than building direct screening relationships entirely alone and independently.
  2. Two candidate diagnostics partners demonstrated screening volume sufficient to support the company's projected first-year commercial patient enrollment targets across all major regions.
  3. Partnership economics remained favorable relative to direct build costs once commercial infrastructure, staffing, and ongoing training expenses were all fully accounted for.
  4. Regulatory timeline modeling confirmed a partnership approach could support commercial launch roughly four months earlier than building capability entirely internally from scratch.
CLIENT PROFILE
The client is a mid-sized specialty biotechnology company generating roughly 310 million dollars in annual revenue (client-reported, unverified by MMA) preparing to launch its recently approved anti-fibrotic therapy for MASH-related cirrhosis. The company lacked established diagnostic screening partnerships and was evaluating whether to build direct elastography relationships or pursue a distribution partnership with an established diagnostics company ahead of commercial launch.
STRATEGIC CHALLENGE
Management needed to decide whether building direct elastography screening partnerships justified the commercial infrastructure investment, given genuine uncertainty about whether a distribution partnership could realistically deliver comparable patient identification speed within the company's targeted launch timeline, available commercial budget, and broader investor expectations for near-term revenue performance and future growth.
MMA APPROACH
MMA benchmarked patient referral volume and screening capability across four candidate diagnostics partners, modeled projected patient identification timelines under direct build and partnership scenarios across multiple regional markets, and assessed regulatory and commercial timeline implications against the company's targeted launch date, available commercial infrastructure budget, and its existing staffing capacity.
KEY FINDINGS
  1. A distribution partnership showed a projected patient identification timeline roughly 30 to 40% faster than building direct screening relationships entirely alone and independently.
  2. Two candidate diagnostics partners demonstrated screening volume sufficient to support the company's projected first-year commercial patient enrollment targets across all major regions.
  3. Partnership economics remained favorable relative to direct build costs once commercial infrastructure, staffing, and ongoing training expenses were all fully accounted for.
  4. Regulatory timeline modeling confirmed a partnership approach could support commercial launch roughly four months earlier than building capability entirely internally from scratch.
RECOMMENDED STRATEGY
Phase 1: Phase 1 (Months 1 to 3): Select the diagnostics partner and finalize screening referral, data-sharing agreements, and the final pricing. Phase 2: Phase 2 (Months 4 to 9): Launch the commercial screening partnership and begin patient identification well ahead of drug launch. Phase 3: Phase 3 (Months 10 to 14): Scale screening volume and expand the partnership to additional regional diagnostic networks and markets.
OUTCOME
The company launched its anti-fibrotic therapy within thirteen months of selecting its diagnostics partner, ahead of the original fourteen month internal build timeline (client-reported, unverified by MMA). The company has since expanded its screening partnership to additional regional diagnostic networks and major hospital systems nationwide.

Frequently Asked Questions

Foundational context covering the market sizes, CAGR, scope, country, region and competition that inform every finding below. This section is provided to cover basics and most often pre-purchase conversations, answered from the MMA Primary Research Dataset.

What is the current size of the Cirrhosis Management Market?

The global cirrhosis management market was valued at approximately $9.8 billion in 2025. Growth is being driven by the first approved anti-fibrotic MASH treatment therapy.

How large will the Cirrhosis Management Market be by 2036?

The market is projected to reach approximately $26.33 billion by 2036, up from $10.72 billion in 2026. This represents nearly two and a half times growth over the ten-year forecast window.

What is the CAGR for the Cirrhosis Management Market 2026 to 2036?

The market is forecast to grow at a CAGR of 9.4% between 2026 and 2036. Bull and bear scenarios range from roughly 8.1% to 10.7%.

Which segment is growing fastest?

Anti-fibrotic and disease-modifying therapies are the fastest-growing segment, expanding at approximately 15.8% annually as adoption accelerates. This is roughly 1.68 times the overall market growth rate.

Who are the major companies in the Cirrhosis Management Market?

Leading companies in this space include Madrigal Pharmaceuticals, Gilead Sciences, Intercept Pharmaceuticals, Novo Nordisk, and Mallinckrodt. Together these five hold roughly 44% of global market share.

Which country is growing fastest?

India is currently the fastest-growing single country, reflecting its rapidly expanding hepatology diagnostic infrastructure and screening reach. Growing viral hepatitis screening access is accelerating this growth further.

Report Segmentation Architecture

The full report scope spans multiple orthogonal segmentation dimensions, with cross-tabulated demand data provided for each dimension pair. Coverage extends further to regional breakdowns, trend trajectories, and the competitive detail needed to support segment-level decision-making.

By Treatment and Product Type

  • Complication Management Therapies
  • Anti-Fibrotic and Disease-Modifying Therapies
  • Antiviral Therapies for Viral Hepatitis-Related Cirrhosis
  • Diagnostic and Non-Invasive Fibrosis Monitoring
  • Liver Transplant Support and Perioperative Management
  • Nutritional and Supportive Care Products

By End-Use Industry

  • Specialist Hepatology Centers
  • Community Gastroenterology Practices
  • Primary Care Screening Programs
  • Academic Transplant Centers

By Commercial Dimension

  • Generic Complication Prescribing
  • Anti-Fibrotic Specialty Pharmacy Distribution
  • Diagnostic Screening Partnership Referrals
  • Outcomes-Based Payer Agreements

By Region

  • North America
  • Western Europe
  • East Asia
  • South Asia and Pacific
  • Latin America
  • Middle East and Africa
  • Eastern Europe

Scope, Methodology, and Coverage

Every figure in this report is reproducible from documented input assumptions. The scope below maps the historical period, the forecast horizon, the segmentation dimensions, and the countries covered, alongside the underlying primary and qualitative methodology.
Historical Period
2020 to 2025
Forecast Period
2026 to 2036
Base Year
2025 (USD billions; MMA Primary Research Dataset, August 2026)
Market Definition
Cirrhosis management covers pharmacological and diagnostic products used to treat liver cirrhosis and its complications, including complication management therapies, anti-fibrotic and disease-modifying drugs, antiviral therapies for viral hepatitis-related cirrhosis, non-invasive fibrosis diagnostics, and transplant support and nutritional care products. It excludes general hepatitis vaccination programs and liver transplant surgical procedures themselves, covering only the pharmacological and diagnostic products supporting the broader care pathway.
Quantitative Units
USD billions (current prices); diagnosed patient population where disclosed
Segmentation Dimensions
By Treatment and Product Type; By End-Use Industry; By Commercial Dimension; By Region
Regions Covered
North America, Western Europe, East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe
Countries Covered
USA, Canada, Mexico, Germany, France, UK, Sweden, China, Japan, South Korea, India, Vietnam, Indonesia, Australia, Brazil, Colombia, Argentina, Saudi Arabia, UAE, Egypt, South Africa, Nigeria, Turkey, Poland, Czechia, Hungary, Romania, Russia, Netherlands, Italy, Spain, and additional markets relevant to this sector
Key Companies Profiled
Madrigal Pharmaceuticals Inc, Gilead Sciences Inc, Intercept Pharmaceuticals (Alfasigma), Novo Nordisk A/S, Mallinckrodt Pharmaceuticals, Bristol Myers Squibb Company, Pfizer Inc, AbbVie Inc, Boehringer Ingelheim GmbH, Akero Therapeutics Inc, 89bio Inc, Viking Therapeutics Inc, CymaBay Therapeutics Inc, Genfit S.A., Inventiva S.A., Echosens, Siemens Healthineers AG, GE HealthCare Technologies Inc, Grifols S.A., Salix Pharmaceuticals (Bausch Health)
Quantitative Methodology
Primary survey, n=3,800 respondents, Q4 2025, six countries; demand-side model with trade association cross-validation
Qualitative Methodology
47 expert interviews, Q4 2025; applied to validate demand model assumptions, identify emerging dynamics, and assess competitive positioning
Report Format
PDF and XLSX data workbook (Word format preview document)
Publisher
Market Minds Advisory
Report Code
MMA-2026-HLT-345
Published
August 2026
Contact
sales@marketmindsadvisory.com | www.marketmindsadvisory.com

Purchase the full Cirrhosis Management Market Report (2026 to 2036).

The full report provides a comprehensive assessment of the global cirrhosis management market, including detailed segmentation by treatment and product type, end-use industry, and commercial dimension across all seven world regions. It profiles twenty leading and emerging developers, benchmarking anti-fibrotic pipeline depth, diagnostic screening partnerships, and South Asian trial infrastructure. The analysis includes ten-year forecasts through 2036 under base, bull, and bear scenarios, alongside primary research findings drawn from MMA's survey of 3,800 respondents and 47 expert interviews conducted in the fourth quarter of 2025. A dedicated input cost section examines clinical trial and manufacturing scale-up exposure across major development programs.
Detailed segment-level ten-year forecasts through 2036
Profiles of twenty leading and emerging developers
Regional analysis spanning all seven world regions
Trial cost and manufacturing risk assessment
Competitive benchmarking on moats and vulnerabilities
Primary survey and expert interview data appendix

Built For The People Who Decide

From boardroom strategy to bench-side execution, this report is read cover-to-cover by leaders shaping the next decade of their industry, turning demand scenarios, market dynamics and valuation benchmarks into decisions.
CXOs/ Presidents/ VPs/ Managers
M&A and Corporate Development
Strategy Teams and R&D Heads
Procurement and Product Directors
Regulatory and Compliance Leaders
Investor Relations and Equity Analysts